Biphasic response of pancreatic β-cell mass to ablation of tuberous sclerosis complex 2 in mice

被引:144
作者
Shigeyama, Yutaka [1 ]
Kobayashi, Toshiyuki [3 ]
Kido, Yoshiaki [1 ]
Hashimoto, Naoko [1 ]
Asahara, Shun-ichiro [1 ]
Matsuda, Tomokazu [1 ]
Takeda, Akihiko [1 ]
Inoue, Tae [1 ]
Shibutani, Yuki [1 ]
Koyanagi, Maki [1 ]
Uchida, Tohru [1 ]
Inoue, Maki [2 ]
Hino, Okio [3 ]
Kasuga, Masato [1 ]
Noda, Tetsuo [2 ]
机构
[1] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet Metab & Endocrinol,Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1358550, Japan
[3] Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 1358550, Japan
关键词
D O I
10.1128/MCB.01695-07
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have demonstrated the importance of insulin or insulin-like growth factor 1 (IGF-1) for regulation of pancreatic beta-cell mass. Given the role of tuberous sclerosis complex 2 (TSC2) as an upstream molecule of mTOR (mammalian target of rapamycin), we examined the effect of TSC2 deficiency on beta-cell function. Here, we show that mice deficient in TSC2, specifically in pancreatic beta cells (beta TSC2(-/-) mice), manifest increased IGF-1-dependent phosphorylation of p70 S6 kinase and 4E-BP1 in islets as well as an initial increased islet mass attributable in large part to increases in the sizes of individual beta cells. These mice also exhibit hypoglycemia and hyperinsulinemia at young ages (4 to 28 weeks). After 40 weeks of age, however, the beta TSC2(-/-) mice develop progressive hyperglycemia and hypoinsulinemia accompanied by a reduction in islet mass due predominantly to a decrease in the number of beta cells. These results thus indicate that TSC2 regulates pancreatic beta-cell mass in a biphasic manner.
引用
收藏
页码:2971 / 2979
页数:9
相关论文
共 32 条
[1]  
Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI200113785
[2]   Reduced TOR signaling extends chronological life span via increased respiration and upregulation of mitochondrial gene expression [J].
Bonawitz, Nicholas D. ;
Chatenay-Lapointe, Marc ;
Pan, Yong ;
Shadel, Gerald S. .
CELL METABOLISM, 2007, 5 (04) :265-277
[3]   Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells [J].
Briaud, I ;
Dickson, LM ;
Lingohr, MK ;
McCuaig, JF ;
Lawrence, JC ;
Rhodes, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (03) :2282-2293
[4]   β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes [J].
Butler, AE ;
Janson, J ;
Bonner-Weir, S ;
Ritzel, R ;
Rizza, RA ;
Butler, PC .
DIABETES, 2003, 52 (01) :102-110
[5]   Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2 [J].
Garami, A ;
Zwartkruis, FJT ;
Nobukuni, T ;
Joaquin, M ;
Roccio, M ;
Stocker, H ;
Kozma, SC ;
Hafen, E ;
Bos, JL ;
Thomas, G .
MOLECULAR CELL, 2003, 11 (06) :1457-1466
[6]   B-CELL SIZE INFLUENCES GLUCOSE-STIMULATED INSULIN-SECRETION [J].
GIORDANO, E ;
CIRULLI, V ;
BOSCO, D ;
ROUILLER, D ;
HALBAN, P ;
MEDA, P .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (02) :C358-C364
[7]   The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins [J].
Harrington, LS ;
Findlay, GM ;
Gray, A ;
Tolkacheva, T ;
Wigfield, S ;
Rebholz, H ;
Barnett, J ;
Leslie, NR ;
Cheng, S ;
Shepherd, PR ;
Gout, I ;
Downes, CP ;
Lamb, RE .
JOURNAL OF CELL BIOLOGY, 2004, 166 (02) :213-223
[8]   Ablation of PDK1 in pancreatic β cells induces diabetes as a result of loss of β cell mass [J].
Hashimoto, N ;
Kido, Y ;
Uchida, T ;
Asahara, SI ;
Shigeyama, Y ;
Matsuda, T ;
Takeda, A ;
Tsuchihashi, D ;
Nishizawa, A ;
Ogawa, W ;
Fujimoto, Y ;
Okamura, H ;
Arden, KC ;
Herrera, PL ;
Noda, T ;
Kasuga, M .
NATURE GENETICS, 2006, 38 (05) :589-593
[9]   PKCλ regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic β cells [J].
Hashimoto, N ;
Kido, Y ;
Uchida, T ;
Matsuda, T ;
Suzuki, K ;
Inoue, H ;
Matsumoto, M ;
Ogawa, W ;
Maeda, S ;
Fujihara, H ;
Ueta, Y ;
Uchiyama, Y ;
Akimoto, K ;
Ohno, S ;
Noda, T ;
Kasuga, M .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) :138-145
[10]  
Herrera PL, 2000, DEVELOPMENT, V127, P2317